Skip to main content

Services of MTRC

10
Jun 2019

MTRC released 15 EU reimbursement system descriptions

Descriptions are available as webinars or presentations in Acrobat PDF. They cover stakeholders, money flow, payment system, innovation funding, funding, and HTA landscape. Currently, overviews are available for 15 EU markets: Austria, Czech Republic, Denmark, England, Finland, France, Germany, Hungary, Italy, Norway, Romania, Spain, Sweden, and Switzerland. In June-July we will add overviews for Belgium, Greece, the Netherlands, Poland, Russia, and Turkey.
06
May 2019

MTRC has launched platform for online education and seminars on market access

We are happy to announce the launch of “Med Tech Market Access Academy” (www.a-marketaccess.com), a unique repository of online courses and seminars on European market access for medical devices and in-vitro diagnostic tests. Seminars are delivered as pre-recorded webinars and cover general introduction into market access, and country-specific overviews. We are launching the platform with 6 seminars (general introduction into market access, and reimbursement overviews in EU5) and expect to add 4-6 seminars each month.
06
May 2019

MTRC has launched the first Youtube channel on market access

We are happy to announce the start of the first Youtube channel dedicated to market access for medical devices, in-vitro diagnostic tests, and e-health solutions, “Market Access Insider”. In the first season of the program, we will weekly release videos of interviews with decision-makers, researchers, consultants, physicians and patient representatives on the topics of the payment system, health insurance, reimbursement pathways, health technology assessment and others in European countries. The first season will include interviews with experts from the Czech Republic, France, Germany, Italy, the Netherlands, and Spain.
04
Oct 2018

Oleg Borisenko co-authored economic analysis for congenital heart defect repair with ADAPT tissue engineered pericardium scaffold

The article "Congenital heart defect repair with ADAPT tissue engineered pericardium scaffold: An early-stage health economic model", published in Plos One presented the cost effectiveness of tissue engineered bovine tissue pericardium scaffold (CardioCel) for the repair of congenital heart defects in comparison with surgery using xenogeneic, autologous, and synthetic patches over a 40-year time horizon from the perspective of the UK National Health Service.